Implementing Genome-Driven Oncology

@article{Hyman2017ImplementingGO,
  title={Implementing Genome-Driven Oncology},
  author={David M. Hyman and Barry S. Taylor and Jos{\'e} Baselga},
  journal={Cell},
  year={2017},
  volume={168},
  pages={584-599}
}
Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genome-driven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and validation, implementing drug combinations, clinical trial designs, targeting tumor heterogeneity, and… CONTINUE READING
BETA

Similar Papers

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 58 CITATIONS, ESTIMATED 52% COVERAGE

Basket Trials for Intractable Cancer

  • Front. Oncol.
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2016
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 19 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 98 REFERENCES

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  • The New England journal of medicine
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL